aod9604 phase 2 trial weight loss results AOD-9604 vs Semaglutide: 0% vs 15% Fat (2026 Data) aod9604 phase 2 trial results

The body clears it too quickly for it to build up significantly between doses, especially when compared to compounds with half-lives measured in days

ie is 150mcg injectable similar to 25mcg oral

Continuous, uninterrupted use beyond 8 weeks has not been characterized in any published model

Preclinical and early human data suggest it may promote lipolysis, inhibit lipogenesis, and preferentially act on adipose tissue by influencing beta3 adrenergicmediated pathways and hormonesensitive lipase activity

They will guide you on how often you should receive the injections based on your unique goals and overall health

Its a more direct and reliable way to ensure your body gets exactly what it needs